ストックスクリーナーアプリを入手
166.08
0.04%
-0.06
プレマーケット:
166.08
Astrazeneca Plc (AZN) 最新ニュース
AstraZeneca stock holds steady amid licensing deal for novel Lp(a) inhibitor - ad-hoc-news.de
AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears - Yahoo Finance
AstraZeneca stock falls as Etcamah trial setback clouds oncology outlook - ad-hoc-news.de
AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open Long (NYSE:AZN) - Seeking Alpha
AstraZeneca breast cancer drug fails late-stage trial goal By Investing.com - Investing.com Nigeria
AstraZeneca's breast cancer pill fails in late-stage trial - Reuters
AstraZeneca's Etcamah fails in late-stage trial as first-line breast cancer treatment - Seeking Alpha
AstraZeneca stock falls after Etcamah trial setback despite strong oncology pipeline - ad-hoc-news.de
AstraZeneca Says Late-Stage Etcamah Breast-Cancer Trial Misses Main Goal - marketscreener.com
AstraZeneca breast cancer drug fails late-stage trial goal - investing.com
AstraZeneca Says Breast Cancer Pill Fails in Key Study - Bloomberg.com
AstraZeneca : Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer - marketscreener.com
Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer - AstraZeneca
Jim Cramer Says He Is Not Going to Put His Money on AstraZeneca (AZN) - Yahoo Finance
AstraZeneca Halts Early Lung Cancer Imaging Trial: What Investors Should Watch Next - TipRanks
Positive Lung Cancer Data Lifts the Case for Amgen and AstraZeneca - Yahoo Finance
AstraZeneca stock gains as analysts see upside ahead of next earnings - ad-hoc-news.de
AstraZeneca stock heads into the open after a modest London gain - ad-hoc-news.de
AstraZeneca stock heads into the open after a 0.93% gain - ad-hoc-news.de
Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion? - Yahoo Finance
AstraZeneca’s New Cholesterol Combo Trial Could Reshape Its Heart-Health Portfolio - TipRanks
Berenberg Notes AstraZeneca's 'Stellar' Tozorakimab Late-stage Data; Buy Retained - marketscreener.com
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff - Zacks Investment Research
AstraZeneca's $5bn drug promise is no 'buy' signal for Deutsche - Proactive financial news
AstraZeneca stock edges higher as Deutsche Bank sticks to Sell after COPD data - ad-hoc-news.de
AstraZeneca stock gains new RBC and Berenberg backing on COPD trial success - ad-hoc-news.de
AstraZeneca PLC : Gets a Sell rating from Deutsche Bank - marketscreener.com
Can AstraZeneca (LSE:AZN) Stock Extend Its Rally On A Fresh Wave Of Oncology Approvals? - Kalkine Media
AstraZeneca stock heads into the open after a modest September 9, 2026 gain - ad-hoc-news.de
AstraZeneca stock heads into the open after a 2.0 percent drop - ad-hoc-news.de
Could AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)? - Yahoo Finance
AstraZeneca Falls 1.3% Despite a 34% COPD Breakthrough - GuruFocus
AstraZeneca Advances TROP2 Testing Standard in Key Lung Cancer Study - TipRanks
AstraZeneca slips Wednesday, underperforms market - MarketWatch
AstraZeneca COPD data back Citi's $7b peak sales case - Proactive Investors
AstraZeneca stock gains analyst support as RBC sets 14,500p target - ad-hoc-news.de
RBC Capital Markets Initiates AstraZeneca Coverage at Outperform - marketscreener.com
AstraZeneca stock holds after RBC starts coverage at GBP145 - ad-hoc-news.de
NEWSLETTER: AstraZeneca drug reduces lung disease flare-ups in late-stage trials - Reuters
RBC Initiates AstraZeneca at Outperform With GBP145 Price Target - marketscreener.com
Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study - Yahoo Finance
Amgen and AstraZeneca report survival improvement in lung cancer trial - Yahoo Finance UK
RBC Capital initiates AstraZeneca stock at Outperform, sets target at £145 By Investing.com - Investing.com Canada
RBC Initiates AstraZeneca at Outperform as Near-term Overhangs Create 'Attractive' Entry Point - marketscreener.com
Amgen and AstraZeneca report positive lung cancer trial results By Investing.com - Investing.com Nigeria
AstraZeneca stock edges lower ahead of the open after Imfinzi trial win - ad-hoc-news.de
Amgen and AstraZeneca report positive lung cancer trial results - investing.com
AstraZeneca Stock: What’s Shaping Investor Attention? - Kalkine Media
AstraZeneca stock heads into the open after a 1.2% slide - AD HOC NEWS
FDA clears Astrazeneca's Etcamah for first-line breast cancer - bioworld.com
AstraZeneca PLC : Gets a Buy rating from RBC - marketscreener.com
AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) CongressSlideshow - Seeking Alpha
AstraZeneca stock dips as new cancer and lung trials reshape the pipeline - AD HOC NEWS
AstraZeneca reports tozorakimab COPD trial results - grafa.com
AstraZeneca falls Tuesday, underperforms market - MarketWatch
Astrazeneca Secures FDA Approval for New Breast Cancer Treatment - Benzinga
AstraZeneca PLC : Buy rating from JP Morgan - marketscreener.com
ERS 2026: AstraZeneca’s IL-33 inhibitor tozorakimab reduces mucus plug burden in COPD - Pharmaceutical Technology
AstraZeneca sees positive results from lung cancer drug trial - Sharecast.com
AstraZeneca's Tozorakimab Shows Promise in COPD Trials, Stock Po - GuruFocus
AstraZeneca and Amgen clear a milestone in small cell lung cancer - marketscreener.com
AstraZeneca’s Lung Disease Drug Shows Broad Benefit in Trials - Bloomberg.com
AstraZeneca's drug combo helps lung cancer patients live longer in late-stage study - London South East
AstraZeneca's Imfinzi Combo Therapy Boosts Survival in Late-stage Small Cell Lung Cancer Study - marketscreener.com
AstraZeneca hails tozorakimab licence application approval in US - London South East
AstraZeneca's cancer drug combo hits main survival goal in late-stage trial - marketscreener.com
AstraZeneca (AZN) says Imfinzi combo extends survival in small cell lung cancer - Stock Titan
AstraZeneca (LSE:AZN) slumps today as combination chatter grips London pharma? - Kalkine Media
REGAstraZeneca PLCImfinzi+Imdelltra improved OS in small cell lung - TradingView
AstraZeneca Says Tozorakimab Cuts COPD Exacerbations in Phase 3 Trials - marketscreener.com
AstraZeneca PLC (AZN.L) stock price, news, quote and history - Yahoo Finance UK
0.39%
1.55%
大文字化:
|
ボリューム (24 時間):